ESC Premium Access

The efficacy and safety of mineralocorticoid-receptor antagonists: spironolactone and eplerenone in resistant hypertension and chronic kidney disease stages 3

Congress Presentation

About the speaker

Mrs Oksana Obertynska

National Pirogov Memorial Medical University, Vinnitsa (Ukraine)
0 follower

14 more presentations in this session

Central-acting aminopeptidase a inhibitors for new treatment of hypertension: from discovery to clinical trial.

Speaker: Doctor R. Hmazzou (Paris, FR)

Thumbnail

Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: A 6-week randomised, multicentre, double-blind study followed by open-label phase

Speaker: Doctor K. Bapatla (Hyderabad, IN)

Thumbnail

Thrombin generation and platelet function in patients on RAAS inhibitors

Speaker: Doctor C. Helten (Duesseldorf, DE)

Thumbnail

Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: a cross-sectional study

Speaker: Doctor E. Chowdhury (Perth, AU)

Thumbnail

Hemodynamic management of resistant hypertension

Speaker: Doctor F. Chacon-Lozsan (Budapest, HU)

Thumbnail

Access the full session

Poster Session 5 - Hypertension treatment: drugs and devices

Speakers: Mrs O. Obertynska, Doctor R. Hmazzou, Doctor K. Bapatla, Doctor C. Helten, Doctor E. Chowdhury...
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb